Literature DB >> 17015627

Glibenclamide, a blocker of K+(ATP) channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasis.

Xenón Serrano-Martín1, Gilberto Payares, Alexis Mendoza-León.   

Abstract

Glibenclamide reduced the rate of lesion growth in BALB/c mice infected with Leishmania (Leishmania) mexicana, the effect was dose dependent, and the highest dose proved more effective than glucantime. Cross-resistance to glucantime was found in animals infected with a glibenclamide-resistant line, but combined therapy reduced lesion progression even in the glibenclamide-resistant strain.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17015627      PMCID： PMC1693980          DOI： 10.1128/AAC.00617-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs.

Authors:  Simon L Croft; Graham H Coombs
Journal:  Trends Parasitol       Date:  2003-11

Review 2.  ABC proteins of Leishmania.

Authors:  D Légaré; S Cayer; A K Singh; D Richard; B Papadopoulou; M Ouellette
Journal:  J Bioenerg Biomembr       Date:  2001-12       Impact factor: 2.945

Review 3.  Drug resistance in leishmaniasis.

Authors:  Simon L Croft; Shyam Sundar; Alan H Fairlamb
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

4.  A comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites.

Authors:  W Huber; J C Koella
Journal:  Acta Trop       Date:  1993-12       Impact factor: 3.112

5.  Biochemistry of Pentostam resistant Leishmania.

Authors:  J D Berman; N Edwards; M King; M Grogl
Journal:  Am J Trop Med Hyg       Date:  1989-02       Impact factor: 2.345

6.  Leishmania sp.: growth and survival are impaired by ion channel blockers.

Authors:  A Ponte-Sucre; Y Campos; M Fernandez; H Moll; A Mendoza-León
Journal:  Exp Parasitol       Date:  1998-01       Impact factor: 2.011

7.  Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin.

Authors:  Benjamin Gourbal; Niluefer Sonuc; Hiranmoy Bhattacharjee; Danielle Legare; Shyam Sundar; Marc Ouellette; Barry P Rosen; Rita Mukhopadhyay
Journal:  J Biol Chem       Date:  2004-05-11       Impact factor: 5.157

Review 8.  Leishmaniasis: efflux pumps and chemoresistance.

Authors:  Clara Leandro; Lenea Campino
Journal:  Int J Antimicrob Agents       Date:  2003-09       Impact factor: 5.283

Review 9.  Biochemistry of arsenic detoxification.

Authors:  Barry P Rosen
Journal:  FEBS Lett       Date:  2002-10-02       Impact factor: 4.124

10.  Synergistic effect of glucantime and a liposome-encapsulated muramyl dipeptide analog in therapy of experimental visceral leishmaniasis.

Authors:  L E Adinolfi; P F Bonventre; M Vander Pas; D A Eppstein
Journal:  Infect Immun       Date:  1985-05       Impact factor: 3.441
View more
  26 in total

1.  Overexpression of specific proton motive force-dependent transporters facilitate the export of surfactin in Bacillus subtilis.

Authors:  Xu Li; Huan Yang; Donglai Zhang; Xue Li; Huimin Yu; Zhongyao Shen
Journal:  J Ind Microbiol Biotechnol       Date:  2014-11-04       Impact factor: 3.346

2.  Inhibition of the nucleotide-binding domain, leucine-rich containing family, pyrin-domain containing 3 inflammasome reduces the severity of experimentally induced acute pancreatitis in obese mice.

Authors:  Jason M York; Karla J Castellanos; Robert J Cabay; Giamila Fantuzzi
Journal:  Transl Res       Date:  2014-08-15       Impact factor: 7.012

3.  The brown seaweed Sargassum hemiphyllum exhibits α-amylase and α-glucosidase inhibitory activity and enhances insulin release in vitro.

Authors:  Pai-An Hwang; Yu-Lan Hung; Yi-Kuan Tsai; Shih-Yung Chien; Zwe-Ling Kong
Journal:  Cytotechnology       Date:  2014-10-26       Impact factor: 2.058

4.  A Therapeutic Insight of Niacin and Coenzyme Q10 Against Diabetic Encephalopathy in Rats.

Authors:  Tarek K Motawi; Hebatallah A Darwish; Manal A Hamed; Nagy S El-Rigal; Asmaa F Aboul Naser
Journal:  Mol Neurobiol       Date:  2016-02-11       Impact factor: 5.590

5.  Glyburide, a NLRP3 Inhibitor, Decreases Inflammatory Response and Is a Candidate to Reduce Pathology in Leishmania braziliensis Infection.

Authors:  Augusto M Carvalho; Fernanda O Novais; Camilla S Paixão; Camila I de Oliveira; Paulo Roberto Lima Machado; Lucas P Carvalho; Phillip Scott; Edgar M Carvalho
Journal:  J Invest Dermatol       Date:  2019-06-25       Impact factor: 8.551

6.  Coenzyme Q10 and niacin mitigate streptozotocin- induced diabetic encephalopathy in a rat model.

Authors:  Tarek K Motawi; Hebatallah A Darwish; Manal A Hamed; Nagy S El-Rigal; Asmaa F Aboul Naser
Journal:  Metab Brain Dis       Date:  2017-05-30       Impact factor: 3.584

7.  Identification of the primary mechanism of action of an insulin secretagogue from meal test data in healthy volunteers based on an integrated glucose-insulin model.

Authors:  Steve Choy; Emilie Hénin; Jan-Stefan van der Walt; Maria C Kjellsson; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-11-24       Impact factor: 2.745

8.  Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis.

Authors:  Xenón Serrano-Martín; Gilberto Payares; Marisel De Lucca; Juan Carlos Martinez; Alexis Mendoza-León; Gustavo Benaim
Journal:  Antimicrob Agents Chemother       Date:  2009-10-05       Impact factor: 5.191

9.  Amiodarone destabilizes intracellular Ca2+ homeostasis and biosynthesis of sterols in Leishmania mexicana.

Authors:  Xenón Serrano-Martín; Yael García-Marchan; Alexis Fernandez; Noris Rodriguez; Hector Rojas; Gonzalo Visbal; Gustavo Benaim
Journal:  Antimicrob Agents Chemother       Date:  2009-01-21       Impact factor: 5.191

10.  Elevated blood glucose is associated with aggravated brain edema in acute stroke.

Authors:  Gabriel Broocks; Andre Kemmling; Jens Aberle; Helge Kniep; Matthias Bechstein; Fabian Flottmann; Hannes Leischner; Tobias D Faizy; Jawed Nawabi; Gerhard Schön; Peter Sporns; Götz Thomalla; Jens Fiehler; Uta Hanning
Journal:  J Neurol       Date:  2019-10-30       Impact factor: 4.849
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.